STOCK TITAN
  1. Home
  2. News
  3. MAIA

MAIA Biotechnology Inc - MAIA STOCK NEWS

Welcome to our dedicated news page for MAIA Biotechnology (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MAIA Biotechnology's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MAIA Biotechnology's position in the market.

News
MAIA Biotechnology Announces $4 Million Registered Direct Offering
Rhea-AI Summary
MAIA Biotechnology, Inc. (NYSE American: MAIA) Announces Registered Direct Offering and Private Placement
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.73%
Tags
offering
-
News
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma
Rhea-AI Summary
MAIA Biotechnology, Inc. (NYSE American: MAIA) announced that the U.S. FDA has granted orphan drug designation to its lead asset THIO for the treatment of glioblastoma. This is the third ODD granted to THIO, highlighting its potential in treating multiple cancer indications. Expected market growth from $2.2 billion to $3.2 billion globally in the next three years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
clinical trial
-
News
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
Rhea-AI Summary
MAIA Biotechnology, Inc. reported a 100% disease control rate in second-line non-small cell lung cancer with their lead asset THIO, along with positive findings in gliomas, pediatric brain cancer, and second-generation THIO-derived cancer therapies. The company also achieved FDA clearance for THIO studies in the U.S. and is experiencing a strong pace of enrollment in their THIO-101 Phase 2 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
earnings
News
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer
Rhea-AI Summary
MAIA Biotechnology reports positive phase 2 clinical trial data on its treatment for non-small cell lung cancer, showing a 100% Disease Control Rate (DCR) in second-line treatment and an 88% DCR in third-line treatment, surpassing standard-of-care rates. The trial is ahead of schedule and aims to evaluate the efficacy of THIO followed by PD-(L)1 inhibition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
clinical trial
-
News
MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO
Rhea-AI Summary
MAIA Biotechnology announces positive results from an investigational new drug-enabling study of its second-generation telomere-targeting agents derived from lipid-modified THIO molecules. The study demonstrated broad-spectrum therapeutically-attractive opportunities for specific telomeric stress-inducing treatments. Initial in vivo evaluation showed potent anticancer activity at relatively low dose levels for one of the lead lipid conjugates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.82%
Tags
none
-
News
MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial
Rhea-AI Summary
MAIA Biotechnology reports positive preliminary efficacy data from Phase 2 clinical trial for NSCLC treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags
clinical trial
News
MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023
Rhea-AI Summary
MAIA Biotechnology announces acceptance of preliminary data from Phase 2 clinical trial at ESMO Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
conferences clinical trial
-
News
MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy
Rhea-AI Summary
MAIA Biotechnology's THIO emerges as potential breakthrough in pediatric brain cancer therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
acquisition
-
News
MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023
Rhea-AI Summary
MAIA Biotechnology to present latest findings on telomere-targeting immunotherapies at International Biochemistry Congress 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
conferences
News
MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer
Rhea-AI Summary
MAIA Biotechnology announces promising results for THIO treatment in Diffuse Intrinsic Pontine Glioma (DIPG) at the Society for Neuro-Oncology's conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
Stock MAIA logo
MAIA Biotechnology Inc

NYSE:MAIA

MAIA Rankings

#4607 Ranked by Market Cap
#4615 Ranked by Stock Gains
N/A Ranked by Dividends

MAIA Stock Data

44.11M
14.55M
21.43%
3.9%
4.22%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Chicago

About MAIA

maia biotechnology, inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. a privately-held company based in chicago, maia is led by a passionate, principled and highly experienced management team with significant drug development experience, committed to advancing promising agents into trials in humans clinical trials. maia’s business strategy is designed to advance a strong value proposition for its portfolio of potentially novel compounds. maia controls risk and enhances its opportunity for success by diversifying and generating this portfolio of assets with a variety of compounds with novel mechanisms of action which have potential activity in multiple tumor types. maia’s business model involves placing drug candidates in their own dedicated, r&d focused subsidiary company, which is supported by the common infrastru